Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2174 for Prevention of Postoperative Nausea and Vomiting in Adults
CTR20240185Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant in postoperative nausea and vomiting (PONV), sponsored by Qilu Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on CTR20240185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240185.